News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
738,749 Results
Type
Article (43719)
Company Profile (473)
Press Release (694545)
Multimedia
Podcasts (124)
Webinars (20)
Section
Business (209328)
Career Advice (2041)
Deals (36153)
Drug Delivery (120)
Drug Development (83977)
Employer Resources (174)
FDA (16699)
Job Trends (15191)
News (354188)
Policy (33283)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2659)
Accelerated approval (37)
Adcomms (28)
Allergies (147)
Alliances (51111)
ALS (179)
Alzheimer's disease (1737)
Antibody-drug conjugate (ADC) (335)
Approvals (16942)
Artificial intelligence (552)
Autoimmune disease (166)
Automation (41)
Bankruptcy (373)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (196)
Biotechnology (331)
Bladder cancer (163)
Brain cancer (61)
Breast cancer (656)
Cancer (4983)
Cardiovascular disease (425)
Career advice (1726)
Career pathing (38)
CAR-T (295)
CDC (47)
Celiac Disease (2)
Cell therapy (789)
Cervical cancer (36)
Clinical research (71503)
Collaboration (1819)
Company closure (4)
Compensation (1195)
Complete response letters (67)
COVID-19 (2775)
CRISPR (102)
C-suite (904)
Cystic fibrosis (152)
Data (6381)
Decentralized trials (2)
Denatured (40)
Depression (145)
Diabetes (507)
Diagnostics (6767)
Digital health (50)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (272)
Drug pricing (196)
Drug shortages (29)
Duchenne muscular dystrophy (247)
Earnings (91529)
Editorial (61)
Employer branding (21)
Employer resources (153)
Events (121134)
Executive appointments (1015)
FDA (19885)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1548)
Gene editing (218)
Generative AI (45)
Gene therapy (651)
GLP-1 (1013)
Government (4765)
Grass and pollen (6)
Guidances (385)
Healthcare (19212)
HIV (64)
Huntington's disease (47)
IgA nephropathy (87)
Immunology and inflammation (280)
Immuno-oncology (63)
Indications (117)
Infectious disease (3056)
Inflammatory bowel disease (202)
Inflation Reduction Act (17)
Influenza (122)
Intellectual property (259)
Interviews (316)
IPO (16933)
IRA (53)
Job creations (3714)
Job search strategy (1440)
JPM (66)
Kidney cancer (16)
Labor market (86)
Layoffs (582)
Leadership (34)
Legal (8028)
Liver cancer (93)
Longevity (14)
Lung cancer (674)
Lymphoma (385)
Machine learning (43)
Management (59)
Manufacturing (828)
MASH (172)
Medical device (13929)
Medtech (13984)
Mergers & acquisitions (20306)
Metabolic disorders (1329)
Multiple sclerosis (168)
NASH (19)
Neurodegenerative disease (346)
Neuropsychiatric disorders (97)
Neuroscience (3046)
Neurotech (1)
NextGen: Class of 2026 (6770)
Non-profit (4586)
Now hiring (68)
Obesity (638)
Opinion (286)
Ovarian cancer (169)
Pain (205)
Pancreatic cancer (236)
Parkinson's disease (298)
Partnered (34)
Patents (511)
Patient recruitment (511)
Peanut (57)
People (60360)
Pharmaceutical (85)
Pharmacy benefit managers (30)
Phase 1 (22488)
Phase 2 (31525)
Phase 3 (23303)
Pipeline (5486)
Policy (301)
Postmarket research (2602)
Preclinical (9613)
Press Release (67)
Prostate cancer (247)
Psychedelics (56)
Radiopharmaceuticals (303)
Rare diseases (907)
Real estate (6065)
Recruiting (71)
Regulatory (25064)
Reports (53)
Research institute (2490)
Resumes & cover letters (354)
Rett syndrome (27)
RNA editing (21)
RSV (80)
Schizophrenia (156)
Series A (257)
Series B (203)
Service/supplier (11)
Sickle cell disease (105)
Special edition (27)
Spinal muscular atrophy (162)
Sponsored (43)
Startups (3806)
State (2)
Stomach cancer (19)
Supply chain (107)
Tariffs (85)
The Weekly (82)
Vaccines (1043)
Venture capital (96)
Weight loss (411)
Women's health (94)
Worklife (19)
Date
Today (101)
Last 7 days (546)
Last 30 days (2361)
Last 365 days (30747)
2026 (3974)
2025 (31063)
2024 (36297)
2023 (41014)
2022 (52277)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33023)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (754)
Alabama (90)
Alaska (7)
Arizona (319)
Arkansas (14)
Asia (40720)
Australia (6767)
California (11595)
Canada (3338)
China (1147)
Colorado (489)
Connecticut (503)
Delaware (342)
Europe (89311)
Florida (1716)
Georgia (363)
Hawaii (3)
Idaho (61)
Illinois (894)
India (69)
Indiana (530)
Iowa (24)
Japan (442)
Kansas (131)
Kentucky (41)
Louisiana (27)
Maine (72)
Maryland (1417)
Massachusetts (8421)
Michigan (330)
Minnesota (644)
Mississippi (5)
Missouri (130)
Montana (34)
Nebraska (28)
Nevada (122)
New Hampshire (83)
New Jersey (3083)
New Mexico (31)
New York (3041)
North Carolina (1550)
North Dakota (9)
Northern California (5648)
Ohio (340)
Oklahoma (21)
Oregon (45)
Pennsylvania (2327)
Puerto Rico (24)
Rhode Island (49)
South America (1122)
South Carolina (66)
South Dakota (1)
Southern California (4500)
Tennessee (178)
Texas (1781)
United States (41249)
Utah (343)
Vermont (1)
Virginia (272)
Washington D.C. (82)
Washington State (961)
West Virginia (4)
Wisconsin (116)
Wyoming (2)
738,749 Results for "nikang therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
NiKang Therapeutics Presents Discovery of NKT5097, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2/4 Dual Degrader for Cancer Therapy at SABCS 2025
December 12, 2025
·
3 min read
Press Releases
NiKang Therapeutics® Completes Dosing of the First Cohort in a Phase 1 Study of NKT5097, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2/4 Dual Degrader
September 9, 2025
·
3 min read
Drug Development
NiKang Therapeutics Doses First Patient in a Phase 1/1b Study of NKT3447, an Oral, Selective Inhibitor of CDK2 Which Reduces Cyclin E Expression
NiKang Therapeutics Inc. (“NiKang”) is a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs.
April 15, 2024
·
3 min read
Business
NiKang Therapeutics Appoints Joanne Lager, M.D., as Chief Medical Officer
NiKang Therapeutics Inc. today announced the appointment of Joanne (Jo) Lager, M.D., as Chief Medical Officer (CMO), reporting to Zhenhai Gao, Ph.D., Co-founder, President and Chief Executive Officer (CEO) of NiKang.
January 4, 2024
·
2 min read
BioCapital
NiKang Therapeutics Presents the Discovery and Unique Mechanism of Action of a Selective CDK2 Inhibitor NKT3447 at AACR Annual Meeting 2024
NiKang Therapeutics Inc. announced today the unveiling of NKT3447 at the American Association for Cancer Research (AACR) Annual Meeting 2024. NKT3447 is an orally bioavailable small molecule CDK2 inhibitor that exhibits high selectivity against CDK1 and other CDK.
April 5, 2024
·
3 min read
Press Releases
NiKang Therapeutics® Completes Dosing of the First Cohort in a Phase 1 Study of NKT3964, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2 Degrader
March 10, 2025
·
3 min read
Press Releases
NiKang Therapeutics® Announces First Patient Dosed in a Phase 1b/2 Study of NKT2152 in Combination with Standard-of-Care in First-Line Regimen for Hepatocellular Carcinoma
January 21, 2025
·
3 min read
Business
NiKang Therapeutics Enters into Clinical Trial Collaboration and Supply Agreement to Evaluate NKT2152 in Combination with Standard-of-Care in First-Line Advanced Hepatocellular Carcinoma
NiKang Therapeutics Inc. today announced that it has entered into a clinical trial collaboration and supply agreement with F. Hoffmann-La Roche Ltd. (“Roche”) to evaluate NKT2152, a small molecule that inhibits hypoxia inducible factor 2α (HIF2α), in combination with standard-of-care atezolizumab (Tecentriq®) and bevacizumab (Avastin®) in first-line treatment of unresectable/advanced hepatocellular carcinoma (HCC).
December 8, 2023
·
2 min read
Business
NiKang Therapeutics Appoints Anne E. Borgman, M.D., to Board of Directors
NiKang Therapeutics Inc. today announced that Dr. Anne Borgman has been appointed to the company’s Board of Directors.
January 18, 2023
·
2 min read
Press Releases
Sale of Intellectual Property – Mythic Therapeutics Inc.
December 23, 2025
·
1 min read
1 of 73,875
Next
